Companies in #GPCR-Targeted Small Molecules
Found 1 company operating in this sector.
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.